Wantai Biological Pharmacy General Manager Jiang Zhiming has resigned for personal reasons, having served less than three years. She took up the general manager role in January 2024, with an original term running to April 2027, and her 2025 pre-tax compensation was 3.2416 million yuan. As the company's 2025 loss widened to 398 million yuan, marking its first loss since listing, Jiang and other senior executives voluntarily gave up their 2025 performance bonuses. Chairman Qiu Zixin will assume the duties of general manager, and the company is working to select a successor as soon as possible. Wantai Biological Pharmacy's nine-valent HPV vaccine has been launched but has yet to generate scaled profits. In the first quarter of 2026, revenue grew 30.6 percent, and the loss narrowed to 42.98 million yuan.
Beijing Wantai Biological Pharmacy Enterprise Co LtdCEO resignation, widened loss, and voluntary bonus forfeiture signal management instability and financial deterioration.